Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Reiners

Showing results (31-40 of 133) with videos related to

Pageof 14
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2005
Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancerMichael Lassmann, Markus Luster, Heribert Hänscheid, et al.
Thyroid : Official Journal of the American Thyroid Association|November 11, 2005
Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administrationMarkus Luster, Ralph Felbinger, Markus Dietlein, et al.
Mutation Research|March 26, 2003
High gradient magnetic cell sorting and internal standardisation substantially improve the assay for somatic mutations at the glycophorin A (GPA) locusKlaus Hempel, Werner Deubel, Reinhard Lorenz, et al.
Endocrine Journal|October 17, 2007
Childhood thyroid cancers and radioactive iodine therapy: necessity of precautious radiation health risk managementAtsushi Kumagai, Christoph Reiners, Valentina Drozd, et al.
Nuclear Medicine and Biology|May 3, 2011
Validation of an amino-acid-based radionuclide therapy plus external beam radiotherapy in heterotopic glioblastoma modelsIna Israel, Georg Blass, Christoph Reiners, et al.
Thyroid : Official Journal of the American Thyroid Association|July 21, 2015
Letter to the Editor Regarding the Article "Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma"Peter Schneider, Rita Schneider, Mara Schneider, et al.
Nuklearmedizin. Nuclear Medicine|June 18, 2004
[Subclinical thyroid disease]Harald Schicha, Christoph Reiners, Ernst Moser, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 10, 2004
Impact of 131I diagnostic activities on the biokinetics of thyroid remnantsMichael Lassmann, Markus Luster, Heribert Hänscheid, et al.
Medizinische Klinik (Munich, Germany : 1983)|September 20, 2005
[The LISA trial-a- randomized, double-blind, placebo-controlled four-arm study of 1,000 patients with nodular goiter in Germany. Study Design and first results of feasibility]Martin Grussendorf, Renate Vaupel, Christoph Reiners, et al.
European Journal of Endocrinology|January 23, 2009
Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastasesFrederik A Verburg, Uwe Mäder, Markus Luster, et al.
Pageof 14

Showing results (31-40 of 133) with videos related to

Sort By:
Pageof 14
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2005
Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancerMichael Lassmann, Markus Luster, Heribert Hänscheid, et al.
Thyroid : Official Journal of the American Thyroid Association|November 11, 2005
Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administrationMarkus Luster, Ralph Felbinger, Markus Dietlein, et al.
Mutation Research|March 26, 2003
High gradient magnetic cell sorting and internal standardisation substantially improve the assay for somatic mutations at the glycophorin A (GPA) locusKlaus Hempel, Werner Deubel, Reinhard Lorenz, et al.
Endocrine Journal|October 17, 2007
Childhood thyroid cancers and radioactive iodine therapy: necessity of precautious radiation health risk managementAtsushi Kumagai, Christoph Reiners, Valentina Drozd, et al.
Nuclear Medicine and Biology|May 3, 2011
Validation of an amino-acid-based radionuclide therapy plus external beam radiotherapy in heterotopic glioblastoma modelsIna Israel, Georg Blass, Christoph Reiners, et al.
Thyroid : Official Journal of the American Thyroid Association|July 21, 2015
Letter to the Editor Regarding the Article "Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma"Peter Schneider, Rita Schneider, Mara Schneider, et al.
Nuklearmedizin. Nuclear Medicine|June 18, 2004
[Subclinical thyroid disease]Harald Schicha, Christoph Reiners, Ernst Moser, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 10, 2004
Impact of 131I diagnostic activities on the biokinetics of thyroid remnantsMichael Lassmann, Markus Luster, Heribert Hänscheid, et al.
Medizinische Klinik (Munich, Germany : 1983)|September 20, 2005
[The LISA trial-a- randomized, double-blind, placebo-controlled four-arm study of 1,000 patients with nodular goiter in Germany. Study Design and first results of feasibility]Martin Grussendorf, Renate Vaupel, Christoph Reiners, et al.
European Journal of Endocrinology|January 23, 2009
Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastasesFrederik A Verburg, Uwe Mäder, Markus Luster, et al.
Pageof 14